x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012012
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB, IP, IF |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro327 of human FAM134B protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | RETREG1 |
| UniProt No. | Q9H6L5 |
| Gene ID | 54463 |
| Gene Description | FAM134B, also referred to as JK-1 and RETREG1, is a cis-Golgi endoplasmic reticulum transmembrane protein that plays a role in ER homeostasis and may contribute to several human diseases. FAM134B contains a conserved LC3 interacting domain that facilitates binding to LC3 and GABARAP family members and targets impaired ER to the autophagosome for degradation by ER-phagy. Deletion of FAM134B leads to ER expansion and stress-induced apoptosis. Expression of FAM134B has been linked to a number of pathological conditions, including viral infection, cancer, and neuronal disorders. FAM134B can potentially inhibit viral infection, as demonstrated by studies of FAM134B knockouts that resulted in significantly higher rates of Ebola virus replication. Mutations in FAM134B that lead to an accumulation of mis-folded proteins have also been associated with neuronal sensory disorders. The expression and mutational state of FAM134B can also have varying effects on cancer. Oncogenic effects of FAM134B were described in esophageal squamous carcinoma; whereas, it appears to have tumor suppressor activity in colorectal cancer. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
